intravenous infusion Articles
Antisoma's CLL tablet approved by US FDA
12 January 2009
CV's ranolazine shortens QT interval
1 September 2008
PharmaMar's Yondelis enters Ph II COG trial
24 March 2008
Novartis' Aclasta cleared in the EU
15 October 2007
Genzyme/Bayer start Ph III alemtuzumab program
1 October 2007
Enrollment opens for ImClone's Ph II IMC-1121B study
3 September 2007
S-P licenses ARA drug from PeriCor
30 July 2007
Japan stock market week to June 18, 2007
25 June 2007
Japan stock market week to June 4, 2007
11 June 2007
FDA approves Novartis' Reclast for Paget's
23 April 2007
Sym001 enters Ph I ITP and HDN trial
19 March 2007
Stock Commentary - New York week to Jan 8, 2007
15 January 2007
ImClone initiates IMC-3G3 Ph I trial
8 January 2007
Genta's Genasense shows preclinical efficacy
20 November 2006
Replagel cleared for pediatric Fabry disease
30 October 2006
MedImmune files IND for MT103 with US FDA
28 August 2006
UCB's Keppra gets expanded indication in EU
1 May 2006
Peregrine initiates Ph I study of Tarvacin vs HCV
15 August 2005
Japan stock market week to April 18
25 April 2005
APP reports start of Ph II trial of Abraxane/Herceptin
18 April 2005
Novartis' Aclasta gets CHMP recommendation
31 January 2005
PharmaMar's Zalypsis moves to Phase I
24 January 2005
ImClone starts patient treatment in IMC-1121B Ph I trial
10 January 2005
Isis' alicaforsen fails in Crohn's disease trials
13 December 2004
Kosan/Roche's KOS-1584 enters clinic
13 December 2004
AstraZeneca completes Cerovive Ph II enrollment early
13 December 2004
Positive results for Dyax/Genzyme's DX-88
22 November 2004
HGS' TRAIL Receptor 1 agonist advances
20 September 2004
New results for sc version of icatibant
19 April 2004
Positive Phase I data for HGS' Abthrax
15 March 2004
Maelor's Volplex for China
1 March 2004
Nastech initiates Ph I PYY3-36 trial
29 September 2003
Chimerix gets $36M NIH grant to develop smallpox therapy
15 September 2003
MedImmune initiates two Ph II trials for Vitaxin
15 September 2003
$3.75M milestone for Isis in HepaSense JV
6 May 2002
Novartis gets OK for new Zometa use
4 March 2002
Novartis' Zometa backed for treatment of bone metastases in USA
11 February 2002
Merck gets US approval for new carbapenem antibiotic
30 November 2001
Elan and Biogen's Antegren to start Phase III trials in MS
17 September 2001
Results from female Fabry disease trial
7 September 2001
EntreMed starts Ph I/II trial of endostatin
13 July 2001
Novogen cleared to start US trials of phenoxodiol
1 February 2001
Bayer gets FDA OK for new Kogenate
3 July 2000
Isis lifted by award of key antisense patent
2 March 2000
Celltech Chiroscience to file for CDP571 approval in 2000
23 November 1999
Novantrone Delays Disability In Progressive MS Patients
18 September 1998
OASIS 2 Supports Refludan Utility In Unstable Angina
1 September 1998
Healthy Second-Quarter Growth For US Drug Firms
29 July 1998
FDA Clears MedImmune's Synagis For RSV
22 June 1998
Integrilin Launched In First Market, The USA
4 June 1998
Aggrastat, Integrilin First ReoPro Competitors
21 May 1998
HMR Launches Tavanic In UK
2 April 1998
R-PR's Lovenox Cleared In USA For Angina
31 March 1998
Round-Up Of Products Entering Clinical Trials
27 January 1998
First Approval And Launch For IDEC's Rituxan
3 December 1997
New Advances In The Treatment Of Sepsis?
9 October 1997
New Data With SB's Hycamtin In SCLC
22 August 1997
UK Launch Of SmithKline Beecham's Hycamtin
17 February 1997
FDA Clears Hybridon's IND For GEM 132
3 February 1997
MedImmune RSV Antibody In Phase III
2 December 1996
ESSENCE Study Finds Lovenox Beats Heparin
25 November 1996
Stepwise Progress Towards Septic Shock Treatment
12 August 1996
Amylin Trials Spark $22 Million From J&J
12 August 1996
Ibandronate Cleared By EMEA
8 July 1996
R-PR Launches Taxotere In USA
17 June 1996
Zeneca's Tomudex Launched In First Market
11 March 1996
Scios Nova: Fiblast news
5 February 1996
Medco's ATP Improves Cancer Prognosis
8 January 1996
Xenova's X-642
4 December 1995
B-MS To Develop GI's New Thrombolytic
30 October 1995
Taxotere Clears Major Marketing Hurdle In USA
23 October 1995
Celltech Antibody Shows Promise In Bowel Disease
2 October 1995
Intron A Gets Backing For Malignant Melanoma
7 August 1995
Medco's Adenoscan Approved By FDA
29 May 1995
Medco's Adenoscan Approved By FDA
29 May 1995
Significant Results For Scios Nova's Natrecor
27 March 1995
R-PR's Irinotecan And Colorectal Cancer
13 February 1995
Amylin Expands AC137 Trials
16 January 1995
CICLOSPORIN'S ROLE IN BOWEL INFLAMMATION
4 July 1994
FURTHER RESULTS FROM THE GISSI-3 STUDY
15 November 1993
PH III RESULTS WITH ANTI-TNF MAb
1 November 1993
AMERSHAM'S METASTRON APPROVED IN USA
28 June 1993
FDA PANEL REJECTS DAUNOXOME NDA
28 June 1993
IL2 UNCERTAIN IN RENAL CELL CARCINOMA?
3 May 1993
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
